Outcomes and Costs Associated With a History of Vancomycin Exposure in Patients With MRSA-Related Complicated Bacteremia and Infective Endocarditis

Clinical Therapeutics

Volumn 33, Issue 10, 2011, Pages 1475-1482

  Brown, Jack ^a,b   Brown, Kristen A ^b,c   Forrest, Alan ^a,d  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

Attributable mortality; Complicated bacteremia; Cumulative exposure; Infective endocarditis; MRSA; Vancomycin

Indexed keywords

VANCOMYCIN;

ADULT; APACHE; ARTICLE; BACTERIAL ENDOCARDITIS; CLINICAL ARTICLE; COMPLICATED BACTEREMIA; CONTROLLED STUDY; DRUG COST; DRUG EXPOSURE; DRUG TREATMENT FAILURE; ELECTRONIC MEDICAL RECORD; FEMALE; HOSPITAL COST; HUMAN; INFECTION COMPLICATION; LENGTH OF STAY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 80054959913     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.08.011     Document Type: Article

References (25)

1. Grundmann H., Aires-de-Sousa M., Boyce J., Tiemersma E. Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet 2006, 368:874-885.
2. Million Lives Campaign. Getting Started Kit: Reduce MRSA Infections 2007, Institute for Healthcare Improvement.
3. Crum N.F., Lee R.U., Thornton S.A., et al. Fifteen-year study of the changing epidemiology of methicillin-resistant Staphylococcus aureus. Am J Med 2006, 119:943-951.
4. Chang S., Sievert D.M., Hageman J.C., et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003, 348:1342-1347.
5. Performance Standards for Antimicrobial Disc Susceptibility Tests 2010, Clinical Laboratory Standards Institute.
6. Lodise T.P., Miller C.D., Graves J., et al. Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2008, 62:1138-1141. 2008.
7. Moise P.A., Smyth D.S., El-Fawal N., et al. Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2008, 61:85-90.
8. Moise-Broder P.A., Sakoulas G., Eliopoulos G.M., et al. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004, 38:1700-1705.
9. Sakoulas G., Eliopoulos G.M., Moellering R.C., et al. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2002, 46:1492-1502.
10. Jones R.N. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 2006, 42(Suppl 1):S13-S24.
11. Renaud B., Brun-Buisson C. Outcomes of primary and catheter-related bacteremia. A cohort and case-control study in critically ill patients. Am J Respir Crit Care Med 2001, 163:1584-1590.
12. Li J.S., Sexton D.J., Mick N., et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000, 30:633-638.
13. Paladino J.A., Gudgel L.D., Forrest A., Niederman M.S. Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia. Chest 2002, 122:1271-1279.
14. The Red Book 2009, Thomson Healthcare, Montvale, NJ.
15. Hatoum H.T. Microcost analysis of inpatient dispensing and administration of oral solids. Am J Hosp Pharm 1990, 47:800-805.
16. Khatib R., Saeed S., Sharma M., et al. Impact of initial antibiotic choice and delayed appropriate treatment on the outcome of Staphylococcus aureus bacteremia. Eur J Clin Microbio Infect Dis 2006, 25:181-185.
17. Rodvold K.A., Blum R.A., Fischer J.H., et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother 1988, 32:848-852.
18. Rotschafer J.C., Crossley K., Zaske D.E., et al. Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations. Antimicrob Agents Chemother 1982, 22:391-394.
19. Hurst A.K., Yoshinaga M.A., Mitani G.H., et al. Application of a Bayesian method to monitor and adjust vancomycin dosage regimens. Antimicrob Agents Chemother 1990, 34:1165-1171.
20. Yang J.C., F A., Moise-Broder P.A. Predictions of vancomycin exposure based on sparse data or demographics alone. Abstract presented at: 110th Meeting of the American Society for Clinical Pharmacology and Therapeutics 2008.
21. Schweizer M.L., Sakoulas G., Furuno J.P., et al. Increased Mortality With Loss of Function of the Accessory Gene Regulator (agr) in Staphylococcus aureus Bacteremia. Abstract presented at: 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2008.
22. Rybak M.J., Lomaestro B.M., Rotscahfer J.C., et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009, 49:325-327.
23. Lodise T.P., Lomaestro B., Graves J., Drusano G.L. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008, 52:1330-1336.
24. Lodise T.P., Patel N., Lomaestro B.M., et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009, 49:507-514.
25. Drusano G.L. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2004, 2:289-300.